BACICLASI
BACICLASI
Baciclasi is a preparation consisting of a suspension of Bacillus Clausii Spores, normal inhabitants of the intestine, with no pathogenic properties. Administered orally, Bacillus Clausii Spores, due to their high resistance to both chemical and physical agents, cross the barrier of the acid gastric juices reaching, unharmed, the intestinal tract where they are transformed into metabolically active vegetative cells.
Therapeutic Uses:
- Treatment and prevention of intestinal dysmicrobism and subsequent endogenous avitaminosis. Coadjuvant treatment to restore the intestinal microbial flora, altered during treatment with antibiotics or chemotherapy.
- Acute and chronic gastrointestinal disorders in infants, attributable to poisoning or intestinal dysmicrobism and avitaminosis.
- Recurrent respiratory tract infections
- Allergic Rhinitis /Allergic disorders
Available Formulations/Strengths:
- 2 billion CFU of poly antibiotic resistant Bacillus clausii / 5 ml oral suspension in Mini bottle.
- 2 billion CFU of poly antibiotic resistant Bacillus clausii per capsule
DISCLAIMER: †BLACICLASI® is a trademark of Sanzyme Private Limited.
Visited 214 times, 1 visit(s) today
Since 1969, when we entered into a Joint Venture with Sankyo (now Daiichi-Sankyo) to make gonadotropins to export to Japan, we’ve been at the forefront of biological hormones, and today we have the necessary technological foundation to do path breaking work.